ASBP
Aspire Biopharma Holdings, Inc.
Biotechnology
Market Cap$7M
5Y Perf.-98.8%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
ASBP vs MNMD vs CMPS vs ATAI
Revenue, margins, valuation, and 5-year total return — side by side.
MNMD
Mind Medicine (MindMed) Inc.
Biotechnology
Market Cap$2.04B
5Y Perf.+178.5%
CMPS
COMPASS Pathways plc
Medical - Care Facilities
Market Cap$902M
5Y Perf.+117.9%
ATAI
Atai Beckley N.V
Medical - Pharmaceuticals
Market Cap$964M
5Y Perf.+158.7%
ASBP vs MNMD vs CMPS vs ATAI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ASBP | MNMD | CMPS | ATAI |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Medical - Care Facilities | Medical - Pharmaceuticals |
| Market Cap | $7M | $2.04B | $902M | $964M |
| Revenue (TTM) | $2K | $0.00 | $0.00 | $3M |
| Net Income (TTM) | $-32M | $-238M | $-288M | $-154M |
| Gross Margin | 45.5% | — | — | -259.1% |
| Operating Margin | -10314.4% | — | — | -34.6% |
| Total Debt | $1M | $0.00 | $21M | $25M |
| Cash & Equiv. | $4K | $258M | $150M | $18M |
ASBP vs MNMD vs CMPS vs ATAI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ASBP
MNMD
CMPS
ATAI
| Stock | Jan 25 | May 26 | Return |
|---|---|---|---|
| Aspire Biopharma Ho… (ASBP) | 100 | 1.2 | -98.8% |
| Mind Medicine (Mind… (MNMD) | 100 | 278.5 | +178.5% |
| COMPASS Pathways plc (CMPS) | 100 | 217.9 | +117.9% |
| Atai Beckley N.V (ATAI) | 100 | 258.7 | +158.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ASBP vs MNMD vs CMPS vs ATAI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CMPS and ATAI are tied at the top with 2 categories each — the right choice depends on your priorities. Atai Beckley N.V is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. MNMD also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
ASBP
Aspire Biopharma Holdings, Inc.
The Secondary Option
ASBP lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
MNMD
Mind Medicine (MindMed) Inc.
The Long-Run Compounder
MNMD is the clearest fit if your priority is long-term compounding.
- 5.1% 10Y total return vs ATAI's -47.7%
- +214.0% vs ASBP's -52.6%
Best for: long-term compounding
CMPS
COMPASS Pathways plc
The Income Pick
CMPS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.33
- EPS growth -33.9%
- Lower volatility, beta 1.33, current ratio 0.77x
- Beta 1.33, current ratio 0.77x
Best for: income & stability and growth exposure
ATAI
Atai Beckley N.V
The Growth Leader
ATAI is the #2 pick in this set and the best alternative if growth and efficiency is your priority.
- -1.9% revenue growth vs ASBP's -13.7%
- -64.3% ROA vs ASBP's -13.2%
Best for: growth and efficiency
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ATAI | -1.9% revenue growth vs ASBP's -13.7% |
| Quality / Margins | CMPS | 1.3% margin vs ASBP's -16K% |
| Stability / Safety | CMPS | Beta 1.33 vs ASBP's 1.74 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | MNMD | +214.0% vs ASBP's -52.6% |
| Efficiency (ROA) | ATAI | -64.3% ROA vs ASBP's -13.2% |
ASBP vs MNMD vs CMPS vs ATAI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
FY 2024
ASBP vs MNMD vs CMPS vs ATAI — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLATAILAGGINGCMPS
Who Leads Where
ATAI leads in 2 of 6 categories
MNMD leads 1 • ASBP leads 0 • CMPS leads 0 • 2 tied
Explore the data ↓CMPSCOMPASS Pathways plc
0leads
ASBPAspire Biopharma Hold…
0leads
MNMDMind Medicine (MindMe…
1leads
ATAIAtai Beckley N.V
2leads
6 Total Categories
CATEGORYLEADERvs MNMDvs ASBPMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ATAI3/5
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ATAI4/8
Total Returns1Y, 3Y, 5Y total returns with dividends
MNMD6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ATAI leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
ATAI and CMPS operate at a comparable scale, with $3M and $0 in trailing revenue. ATAI is the more profitable business, keeping -51.1% of every revenue dollar as net income compared to ASBP's -16352.0%.
| Metric | ASBPAspire Biopharma … | MNMDMind Medicine (Mi… | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V |
|---|---|---|---|---|
| RevenueTrailing 12 months | $1,941 | $0 | $0 | $3M |
| EBITDAEarnings before interest/tax | -$28M | -$191M | -$179M | -$103M |
| Net IncomeAfter-tax profit | -$32M | -$238M | -$288M | -$154M |
| Free Cash FlowCash after capex | -$4M | -$174M | -$157M | -$90M |
| Gross MarginGross profit ÷ Revenue | +45.5% | — | — | -2.6% |
| Operating MarginEBIT ÷ Revenue | -10314.4% | — | — | -34.6% |
| Net MarginNet income ÷ Revenue | -16352.0% | — | — | -51.1% |
| FCF MarginFCF ÷ Revenue | -1811.5% | — | — | -29.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | +17.7% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -163.0% | -58.7% | -75.0% |
ATAI leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
Evenly matched — MNMD and ATAI each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ASBPAspire Biopharma … | MNMDMind Medicine (Mi… | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V |
|---|---|---|---|---|
| Market CapShares × price | $7M | $2.0B | $902M | $964M |
| Enterprise ValueMkt cap + debt − cash | $9M | $1.8B | $774M | $971M |
| Trailing P/EPrice ÷ TTM EPS | -0.60x | -10.04x | -3.05x | -4.31x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — | — | 3130.37x |
| Price / BookPrice ÷ Book value/share | — | 5.56x | — | 5.51x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
Evenly matched — MNMD and ATAI each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
ATAI leads this category, winning 4 of 8 comparable metrics.
Profitability & Efficiency
ATAI delivers a -96.4% return on equity — every $100 of shareholder capital generates $-96 in annual profit, vs $-3 for CMPS. On the Piotroski fundamental quality scale (0–9), MNMD scores 3/9 vs ATAI's 2/9, reflecting mixed financial health.
| Metric | ASBPAspire Biopharma … | MNMDMind Medicine (Mi… | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V |
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -102.5% | -3.4% | -96.4% |
| ROA (TTM)Return on assets | -13.2% | -70.7% | -106.8% | -64.3% |
| ROICReturn on invested capital | — | -3.9% | — | -45.0% |
| ROCEReturn on capital employed | — | -52.2% | -2.5% | -50.4% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 | 2 | 2 |
| Debt / EquityFinancial leverage | — | — | — | 0.21x |
| Net DebtTotal debt minus cash | $1M | -$258M | -$129M | $7M |
| Cash & Equiv.Liquid assets | $3,633 | $258M | $150M | $18M |
| Total DebtShort + long-term debt | $1M | $0 | $21M | $25M |
| Interest CoverageEBIT ÷ Interest expense | -9.19x | -21.81x | -52.40x | -68.93x |
ATAI leads this category, winning 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
MNMD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MNMD five years ago would be worth $4,205 today (with dividends reinvested), compared to $135 for ASBP. Over the past 12 months, MNMD leads with a +214.0% total return vs ASBP's -52.6%. The 3-year compound annual growth rate (CAGR) favors MNMD at 82.7% vs ASBP's -76.2% — a key indicator of consistent wealth creation.
| Metric | ASBPAspire Biopharma … | MNMDMind Medicine (Mi… | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +13.1% | +51.7% | +43.4% | +3.6% |
| 1-Year ReturnPast 12 months | -52.6% | +214.0% | +151.1% | +188.5% |
| 3-Year ReturnCumulative with dividends | -98.7% | +510.3% | +11.0% | +99.5% |
| 5-Year ReturnCumulative with dividends | -98.7% | -57.9% | -72.4% | -79.8% |
| 10-Year ReturnCumulative with dividends | -98.7% | +512.1% | -67.6% | -47.7% |
| CAGR (3Y)Annualised 3-year return | -76.2% | +82.7% | +3.5% | +25.9% |
MNMD leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MNMD and CMPS each lead in 1 of 2 comparable metrics.
Risk & Volatility
CMPS is the less volatile stock with a 1.33 beta — it tends to amplify market swings less than ASBP's 1.74 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MNMD currently trades 98.1% from its 52-week high vs ASBP's 6.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ASBPAspire Biopharma … | MNMDMind Medicine (Mi… | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.74x | 1.68x | 1.33x | 1.48x |
| 52-Week HighHighest price in past year | $2.45 | $21.09 | $10.21 | $6.75 |
| 52-Week LowLowest price in past year | $0.05 | $6.03 | $2.25 | $1.29 |
| % of 52W HighCurrent price vs 52-week peak | +6.3% | +98.1% | +92.0% | +59.4% |
| RSI (14)Momentum oscillator 0–100 | 29.8 | 64.9 | 68.1 | 51.5 |
| Avg Volume (50D)Average daily shares traded | 15.0M | 792K | 3.7M | 6.0M |
Evenly matched — MNMD and CMPS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: MNMD as "Buy", CMPS as "Buy", ATAI as "Buy". Consensus price targets imply 199.3% upside for ATAI (target: $12) vs -3.3% for MNMD (target: $20).
| Metric | ASBPAspire Biopharma … | MNMDMind Medicine (Mi… | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $20.00 | $17.83 | $12.00 |
| # AnalystsCovering analysts | — | 1 | 13 | 4 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +100.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ATAI leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MNMD leads in 1 (Total Returns). 2 tied.
Best OverallAtai Beckley N.V (ATAI)Leads 2 of 6 categories
Loading custom metrics...
ASBP vs MNMD vs CMPS vs ATAI: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is ASBP or MNMD or CMPS or ATAI a better buy right now?
Analysts rate Mind Medicine (MindMed) Inc.
(MNMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ASBP or MNMD or CMPS or ATAI?
Over the past 5 years, Mind Medicine (MindMed) Inc.
(MNMD) delivered a total return of -57. 9%, compared to -98. 7% for Aspire Biopharma Holdings, Inc. (ASBP). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus ASBP's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ASBP or MNMD or CMPS or ATAI?
By beta (market sensitivity over 5 years), COMPASS Pathways plc (CMPS) is the lower-risk stock at 1.
33β versus Aspire Biopharma Holdings, Inc. 's 1. 74β — meaning ASBP is approximately 31% more volatile than CMPS relative to the S&P 500.
04Which is growing faster — ASBP or MNMD or CMPS or ATAI?
On earnings-per-share growth, the picture is similar: COMPASS Pathways plc grew EPS -33.
9% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ASBP or MNMD or CMPS or ATAI?
Mind Medicine (MindMed) Inc.
(MNMD) is the more profitable company, earning 0. 0% net margin versus -16352. 0% for Aspire Biopharma Holdings, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MNMD leads at 0. 0% versus -10314. 4% for ASBP. At the gross margin level — before operating expenses — ATAI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ASBP or MNMD or CMPS or ATAI?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ASBP or MNMD or CMPS or ATAI better for a retirement portfolio?
For long-horizon retirement investors, Mind Medicine (MindMed) Inc.
(MNMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+512. 1% 10Y return). Aspire Biopharma Holdings, Inc. (ASBP) carries a higher beta of 1. 74 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MNMD: +512. 1%, ASBP: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ASBP and MNMD and CMPS and ATAI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.